<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369875</url>
  </required_header>
  <id_info>
    <org_study_id>110163</org_study_id>
    <secondary_id>11-C-0163</secondary_id>
    <nct_id>NCT01369875</nct_id>
  </id_info>
  <brief_title>Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma</brief_title>
  <official_title>Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor
      tissue. The cells are modified to help them kill tumor cells, then given back to the person
      with cancer. By giving these cells to patients, researchers hope to improve the current
      treatments available for patients with melanoma that has not responded to standard therapies.
      The TIL will be given after treatments that will suppress the immune system. This makes it
      easier for the TIL to attack the cancer cells. The TIL will also be given with aldesleukin
      (IL-2), which is designed to help keep the TIL cells alive in the body.

      Objectives:

      - To study the safety and effectiveness of specially modified tumor infiltrating lymphocytes
      to treat melanoma that has not responded to other treatments.

      Eligibility:

      - Individuals at least 18 years of age who have metastatic melanoma that has not responded to
      other treatments.

      Design:

        -  Participants will be screened with a physical exam and medical history. They will also
           have blood tests and imaging studies.

        -  A piece of tumor will be collected and white blood cells will be separated to make the
           TIL for the treatment.

        -  Participants will take drugs to suppress the immune system for 7 days before the start
           of treatment.

        -  Participants will receive the TIL in a single dose. Then they will receive IL-2 every 8
           hours for up to 15 doses. Participants will remain in the hospital for up to 2 weeks
           after treatment. They will be monitored with frequent blood tests and other studies.

        -  After leaving the hospital, participants will have regular followup visits every 1 to 4
           months for the first year. Then they will return for followup every 3 to 4 months, as
           directed by the study researchers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Tumor Infiltrating Lymphocyte (TIL) administration and high dose interleukin (IL)-2
           following lymphodepletion can mediate durable complete responses in patients with
           refractory melanoma. Obstacles to administration of this therapy include failure to
           establish TIL in vitro for about 20% of patients, long delays between tumor resection
           and TIL establishment resulting in poor TIL attributes for therapy and patient
           ineligibility due to progression, and requirements for large numbers of feeder cells for
           TIL expansion to therapeutic numbers.

        -  The K562 cell line was engineered to express the 4-1BBL costimulatory molecule and CD64
           (the high affinity Fc receptor for loading with antibodies such as OKT3). The
           K562.CD64.4-1BBL Engineered Cells with Costimulation Enhancement (ECCE) replaced up to
           75% of feeder cells in large scale TIL expansions. ECCE added to tumor cell suspensions
           provided costimulation in trans resulting in rapid and reliable lymphocyte growth even
           from tumors with no TIL growth under standard conditions.

        -  A cloned K562.CD64.4-1BBL-7F11 ECCE line was produced under Good Manufacturing Practice
           (GMP) conditions and a master cell bank has been generated. An optimized protocol was
           established to rapidly expand (REP) young TIL using minimum feeders and 7F11. These ECCE
           REPed TIL retained tumor recognition and some other attributes of standard TIL, but
           differed from standard TIL by containing fewer CD4+ cells and more natural killer cells.

      When 7F11ECCE were added directly to single cell tumor suspensions, young TIL cultures were
      reliably generated even from patients who otherwise would not have a standard young TIL
      culture for treatment.

      Objectives:

      Primary objectives:

        -  In cohort 1, to evaluate whether young TIL that are rapidly expanded using 7F11 ECCE to
           replace some feeder cells and administered with IL-2 in patients following a non
           -myeloablative conditioning regimen will result in clinical tumor regression in patients
           with refractory metastatic melanoma.

        -  In Cohort 2, to evaluate whether young TIL generated using in trans costimulation with
           7F11 ECCE in patients for whom standard young TIL did not grow can mediate tumor
           regression after a nonmyeloablative conditioning with high dose IL-2 in patients with
           refractory metastatic melanoma.

        -  Determine the toxicity of ECCE young TIL in these treatment regimens

      Eligibility:

      Patients who are 18 years of age or older must have:

        -  metastatic melanoma;

        -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        -  One or more lesions 2 cm or greater suitable for resection for TIL culture

      Patients may not have:

        -  Concurrent major medical illnesses;

        -  Any form of immunodeficiency;

        -  Severe hypersensitivity to any of the agents used in this study;

        -  Contraindications for high dose IL-2 administration.

      Design:

        -  Patients will undergo resection to obtain tumor for generation of autologous young TIL
           cultures.

        -  Parallel TIL cultures will be established using a) the standard technique with IL-2 only
           and b) the Engineered Cells with Costimulation Enhancement (ECCE) protocol using
           irradiated K562.CD64.4-1BBL-7F11 (7F11) cells.

        -  After 10 to 20 days cultures will undergo evaluation for TIL establishment. Standard TIL
           will be used preferentially and patients who have TIL established by standard methods
           will be assigned to Cohort 1

        -  Cohort 1:

             -  TIL will undergo ECCE REP by exposure to OKT-3, IL-2, feeder cells and irradiated
                7F11.

             -  Patients will receive a non-myeloablative lymphocyte depleting preparative regimen
                of cyclophosphamide (60 mg/kg/day intravenous (IV)) on days -7 and -6 and
                fludarabine (25 mg/m^2/day IV) on days -5 through -1.

             -  On day 0 patients will receive the infusion of autologous young TIL and then begin
                highdose aldesleukin (720,000 IU/kg IV every 8 hours for up to 15 doses).

             -  Clinical and immunologic response will be evaluated about 4-6 weeks after
                treatment.

             -  Using an optimal two-stage Phase II design, initially 18 patients will be enrolled,
                and if three or more of the first 18 patients have a clinical response (partial
                response (PR) or complete response (CR)), accrual will continue to 35 patients,
                targeting a 30% goal for objective response.

        -  If standard young TIL fail to grow then ECCE young TIL will be evaluated and patients
           who have ECCE TIL available will be assigned to Cohort 2 .

        -  Cohort 2:

             -  Cultures from patients in Cohort 2 will be evaluated for ECCE TIL establishment. If
                adequate ECCE TIL are available, TIL will undergo ECCE REP by exposure to OKT-3,
                IL-2, feeder cells and irradiated 7F11.

             -  Patients will receive a non-myeloablative lymphocyte depleting preparative regimen
                of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25
                mg/m^2/day IV) on days -5 through -1.

             -  On day 0 patients will receive the infusion of autologous young TIL and then begin
                highdose aldesleukin (720,000 IU/kg IV every 8 hours for up to 15 doses).

             -  Clinical and immunologic response will be evaluated about 4-6 weeks after TIL
                infusion.

             -  Using a small optimal two-stage Phase II design, initially 9 patients will be
                enrolled, and if one or more of the first 9 patients has a clinical response (PR or
                CR), accrual will continue to 24 patients, targeting a 25% goal for objective
                response.

        -  If TIL cultures were not established by either standard methods or ECCE young TIL
           protocols, patients will be eligible for re-resection and evaluation of TIL from a
           different site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Tumor Regression.</measure>
    <time_frame>3 years</time_frame>
    <description>Clinical tumor regression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progression (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6</description>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)</description>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)</description>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor Infiltrating Lymphocytes</intervention_name>
    <description>Intravenous (IV) over 30 minutes on day 0</description>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <arm_group_label>ECCE Young TIL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Measurable metastatic melanoma with at least one lesion that is resectable for
                  tumor infiltrating lymphocytes (TIL) generation.

               2. Patients with 3 or less brain metastases are eligible. Note: If lesions are
                  symptomatic or greater than or equal to 1 cm each, these lesions must have been
                  treated and stable for 3 months for the patient to be eligible.

               3. Greater than or equal to 18 years of age.

               4. Willing to sign a durable power of attorney

               5. Able to understand and sign the Informed Consent Document

               6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

               7. Life expectancy of greater than three months.

               8. Patients of both genders must be willing to practice birth control from the time
                  of enrollment on this study and for up to four months after receiving the
                  preparative regimen.

               9. Serology:

                    1. Seronegative for human immunodeficiency virus (HIV) antibody. (The
                       experimental treatment being evaluated in this protocol depends on an intact
                       immune system. Patients engineered cells with costimulation enhancement
                       (ECCE) TIL 14 who are HIV seropositive can have decreased immune-competence
                       and thus be less responsive to the experimental treatment and more
                       susceptible to its toxicities.)

                    2. Seronegative for hepatitis B antigen, and seronegative for hepatitis C
                       antibody. If hepatitis C antibody test is positive, then patient must be
                       tested for the presence of antigen by reverse transcription polymerase chain
                       reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA)
                       negative.

                    3. Women of child-bearing potential must have a negative pregnancy test because
                       of the potentially dangerous effects of the preparative chemotherapy on the
                       fetus.

              10. Hematology:

                    1. Absolute neutrophil count greater than 1000/mm^3 without the support of
                       filgrastim.

                    2. White blood cell (WBC) (&gt; 3000/mm^3).

                    3. Platelet count greater than 100,000/mm^3.

                    4. Hemoglobin greater than 8.0 g/dl.

              11. Chemistry:

                    1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less
                       or equal to 2.5 times the upper limit of normal.

                    2. Serum creatinine less than or equal to 1.6 mg/dl.

                    3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
                       Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

              12. More than four weeks must have elapsed since any prior systemic therapy at the
                  time the patient receives the preparative regimen, and patients' toxicities must
                  have recovered to a grade 1 or less (except for toxicities such as alopecia or
                  vitiligo). Patients may have undergone minor surgical procedures within the past
                  3 weeks, as long as all toxicities have recovered to grade 1 or less.

              13. Six weeks must have elapsed since any prior anti-cytotoxic T-lymphocyte antigen 4
                  (CTLA4) antibody therapy to allow antibody levels to decline.

              14. Patients who have previously received any anti-CTLA4 antibody and have documented
                  gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic
                  biopsies.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

          2. Systemic steroid therapy required.

          3. Active systemic infections, coagulation disorders or other major medical illnesses of
             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
             arrhythmias, obstructive or restrictive pulmonary disease.

          4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          5. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who ECCE TIL 15 have
             decreased immune competence may be less responsive to the experimental treatment and
             more susceptible to its toxicities).

          6. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          7. History of coronary revascularization or ischemic symptoms

          8. Any patient known to have an left ventricular ejection fraction (LVEF) less than or
             equal to 45%.

          9. Documented LVEF of less than or equal to 45% tested in patients with:

               -  Clinically significant atrial and/or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block

               -  Age greater than or equal to 60 years old

         10. Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted
             tested in patients with:

               -  A prolonged history of cigarette smoking

               -  Symptoms of respiratory dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Rosenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0163.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.</citation>
    <PMID>17237035</PMID>
  </reference>
  <reference>
    <citation>Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105-16. Review.</citation>
    <PMID>10561265</PMID>
  </reference>
  <reference>
    <citation>Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007 Feb 1;109(3):455-64. Review.</citation>
    <PMID>17200963</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2013</results_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Rosenberg, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Skin Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="P2">
          <title>ECCE Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="B2">
          <title>ECCE Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0"/>
                    <measurement group_id="B2" value="46.0"/>
                    <measurement group_id="B3" value="48.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Tumor Regression.</title>
        <description>Clinical tumor regression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progression (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
          <group group_id="O2">
            <title>ECCE Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tumor Regression.</title>
          <description>Clinical tumor regression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progression (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
          <group group_id="O2">
            <title>ECCE Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="E2">
          <title>ECCE Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Rosenberg</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-4164</phone>
      <email>sar@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

